24-Nov-2020 - Wacker Chemie AG

CureVac and WACKER Sign Manufacturing Contract for CureVac’s COVID-19 Vaccine Candidate

Manufacturing at WACKER’s Biotech Site in Amsterdam is Scheduled to Start in the First Half of 2021

CureVac N.V. and Wacker Chemie AG announced that they had signed a contract for the manufacturing of CureVac’s COVID-19 vaccine candidate CVnCoV.

Under the terms of the initial agreement, WACKER will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV at its biotech site in Amsterdam in the first half of 2021. Preparations for the start of production, technology transfers and test runs are already underway. It is planned to produce more than 100 million doses of the CureVac vaccine per year at WACKER’s Amsterdam site. There is also further potential for expansion at the site in order to meet rising demand in the future.

WACKER’s CEO Rudolf Staudigl said: “We are proud and highly motivated to make a contribution to the fight against the spread of the coronavirus pandemic together with CureVac.” As a CDMO (Contract Development and Manufacturing Organization), Wacker Biotech bundles WACKER Group’s biopharmaceutical activities. Its Amsterdam site has been producing vaccines for clinical development and commercial supply for 20 years. The portfolio ranges from conventional live and killed vaccines to protein-based, polysaccharide and glycoconjugate vaccines. In recent months, WACKER has invested in the site to extend production to include mRNA-based vaccines. This new class of vaccines expands the broad vaccine portfolio Wacker Biotech offers to its customers.

Dr. Florian von der Mülbe, Chief Production Officer of CureVac, added: “With WACKER, we have found a committed and highly experienced partner for the production of our vaccine candidate in the Netherlands.” CureVac is building an integrated European vaccine manufacturing network with several CDMO partners. With this strategy, the company will significantly increase the manufacturing capacity already existing within CureVac for CVnCoV up to several hundred million doses per year and will manage potential supply chain risks by working with several partners for each of the key manufacturing process steps.

Facts, background information, dossiers
  • CureVac
  • Wacker Chemie
  • Covid-19
  • mRNA vaccines
More about Wacker
  • News

    WACKER Invests in Amsterdam Biotech Site

    WACKER, the Munich-based chemicals Group, is investing in its production facilities for biologics, LMPs (live microbial products) and vaccines at its Amsterdam site. Projects include the construction of a new fermentation line with a volume of 1,500 liters as well as the setting up of new c ... more

    SynCo Bio Partners B.V. is Now Wacker Biotech B.V.

    As of November 1, 2018, the pharmaceutical protein production facility in the Netherlands acquired by WACKER with its takeover of SynCo Bio Partners Luxembourg S.à r.l., will be renamed Wacker Biotech B.V. The site in Amsterdam for the manufacture of biopharmaceuticals, live microbial produ ... more

    WACKER Invests in Jena Biotech Site

    In Jena, the Munich-based chemical group WACKER has enhanced its production facilities for biopharmaceuticals – also known as biologics – with new equipment. Furthermore, an inspection by the Brazilian health authority ANVISA assessing the site’s quality standards was a major success. “In ... more

  • Companies

    Wacker Biotech GmbH


    Wacker Biotech B.V.

    SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience with mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producin ... more

More about CureVac
  • News

    CureVac’s COVID-19 Vaccine Candidate Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

    CureVac N.V. announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. Furthermore, rhesus macaques were shown to be protected from challenge infection with SARS-CoV-2 f ... more

    CureVac Commences Global Pivotal Phase 2b/3 Trial

    CureVac N.V. announced that it has enrolled the first participant in the pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The randomized, observer blind, placebo-controlled Phase 2b/3 trial called HERALD will assess the safety and efficacy of CVnCoV in adult ... more

    CureVac expands management board

    CureVac N.V. announced that Antony Blanc, PhD, was appointed Chief Business Officer and Chief Commercial Officer of CureVac. In this role, he will be responsible for building the network of partnerships that will support the growth of CureVac, for developing the competitiveness and commerci ... more

  • Companies

    CureVac AG

    CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 18 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the hum ... more